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Abstract Platelet glyeoprotein (GP) IIb-IIIa complex (anb133- 
integrin) changes its conformation upon platelet activation that 
results in binding of RGD-containing ligands and expression of 
ligand-induced binding site (LIBS) neoepitopes. Anti-GIIb-HIa 
monoclonal antibody (monAB) CRC54 bound to -<10% of 
GPIIb-IIIa on resting platelets but binding was enhanced by the 
occupation of GPIIb-IIIa with RGDS peptide and by platelet 
activation indicating that CRC54 is directed against LIBS 
epitope. The epitope was located within the first 100 N-terminal 
residues of GPIIIa and differed from other LIBS epitopes. 
CRC54 as well as its Fab fragments were able to induce platelet 
aggregation. CRC54 also stimulated interaction of GPIlb-IIIa 
with its ligands (fibrinogen and fibronectin) and conformation- 
dependent antibodies. The results indicated that changes of 
GPIIb-IIIa conformation, binding of ligands and platelet 
aggregation could be stimulated via interaction of anti-LIBS 
antibody with the N-terminal part of GPHIa. 
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the ligand-binding site accessible only after agonist-induced 
activation of the complex [9,10] or against LIBS epitopes 
[4-6]. Some anti-LIBS antibodies could stimulate binding ac- 
tivity of GPIIb-IIIa and subsequent platelet aggregation 
[6,11]. Activating monABs are also able to aggregate cells 
expressing recombinant GPIIb-IIIa [12] and to stimulate fibri- 
nogen binding to isolated GPIIb-IIIa [11], indicating that 
GPIIb-IIIa could be activated without involvement of intra- 
cellular pathways. LIBS epitopes are located on both GPIIb 
and GPIIIa components of the complex [4-6,13]. One of them 
was mapped to the C-terminus of the GPIIb heavy chain [14] 
and one to the GPIIIa region adjacent to the membrane do- 
main [15]. However, localization of most regions sensitive to 
the occupation of GPIIb-IIIa is still unknown. 
In this study using monAB against he N-terminal part of 
GPIIIa it was shown that this region contains the LIBS epi- 
tope and that interaction of monAB with this epitope induced 
conformational changes in GPIIb-IIIa, stimulation of ligand 
binding and platelet aggregation. 
1. Introduction 
The main platelet integrin, Ca-dependent glycoprotein (GP) 
l ib-I l ia complex (aiib13a-integrin), is present on the platelet 
surface in a resting form unable to bind adhesive ligands. 
However, agonist-induced platelet activation leads to confor- 
mational changes in GPIIb-IIIa resulting in the opening of the 
ligand-binding pocket, binding of fibrinogen and other RGD- 
containing plasma proteins and platelet aggregation (reviews 
[1-3]). Ligand binding induces additional conformational 
changes which cause exposure of ligand-induced binding sites 
(LIBS) neoepitopes [4-6]. Similar transformations of GPIIb- 
I l ia are stimulated via occupation of the receptor by RGD 
peptides [4-6] or peptidomimetics [7]which bind to a resting 
form of the complex. Alterations in GPIIb-IIIa are also in- 
duced by platelet adhesion [8]. 
Conformational changes in GPIIb-IIIa could be detected 
using conformation-dependent monoclonal antibodies (mon- 
ABs). These antibodies are directed against epitopes within 
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2. Materials and methods 
2.1. Monoclonal and polyclonal antibodies 
MonAB CRC54 is directed against GPIIIa and has been partially 
described previously [8]. Antibody pl-80 [13] and antibody PMI-1 
[4,14] are directed against LIBS epitopes on GPIIb, antibodies 
LIBSI, LIBS2, and LIBS6 against LIBS epitopes on GPIIIa [5], 
and antibody pl-55 recognizes the activated conformation of GPIIb- 
Ilia [10]. Antibodies LIBS1, LIBS2, LIBS6 and PMI-1 were a gener- 
ous gift of Dr. Mark Ginsberg (Scripps Clinic, La Jolla, CA, USA). 
Antibody CRC64 is directed against GPIIb-IIIa complex and inhib- 
ited platelet aggregation [8,16] and control anti-GPIIb-IIIa ntibody 
VM16a has no effects on platelet aggregation [17]. Polyclonal anti- 
GPIIb-IIIa antibodies were produced as described elsewhere [18]. 
2.2. Preparation of Fab fragments 
Fab fragments of monAB CRC54 were prepared by papain diges- 
tion. CRC54 was incubated with papain (Serva, Germany) at a ratio 
of 20/1 (w/w) in 0.2 mM phosphate buffer, 2 mM EDTA, 10 mM 
cysteine, pH 7.4 for 24 h at 37°C. Reaction was stopped by 20 mM 
iodoacetic acid and Fab fragments were purified by FPLC. 
2.3. Platelets 
Platelet-rich plasma (PRP) and washed platelets were prepared 
from the blood of healthy donors as previously described [19]. 
Washed platelets were resuspended in Tyrode/HEPES solution (137 
mM NaC1, 2.7 mM KC1, 0.36 mM NaH2PO4, 0.1% dextrose, 5 mM 
HEPES, pH 7.35) with 2 mM CaCI2 and 1 mM MgC12. In some 
experiments divalent cations were omitted and EDTA was added at 
the concentration of 5 mM. For aggregation and adhesion studies 
Tyrode/HEPES was supplemented with 0.35% BSA and for binding 
and capture assays with 1% BSA. When the effects of deoxyglucose 
All rights reserved. 
A.V. Mazurov et al.IFEBS Letters 391 (1996) 84~8 85 
were studied dextrose was omitted from all solutions. In some experi- 
ments platelets were labeled with 51Cr as described elsewhere [8]. 
2.4. Binding assays 
Labeling of monABs, Fab fragments and fibrinogen (Calbiochem, 
USA) with 1251 and binding experiments were performed essentially as 
described elsewhere [8,19]. Washed platelets (109/ml) were preincu- 
bated without any additions or in the presence of RGDS, RGES 
(both peptides were generously provided by Dr. G. Bespalova, Car- 
diology Research Center, Moscow, Russia), CRC54 or EDTA for 30 
min at 37°C and with thrombin (Sigma, St. Louis, MO) for 5 min at 
22°C. After preincubation 125I-labeled monABs or Fab fragments 
were added in 50 ~1 of Tyrode/HEPES/BSA to 50 ~tl of platelets, 
incubated for 30 rain at 37°C or for 20 min at 22°C (incubation 
with thrombin) and then bound and unbound radioactivities were 
separated by centrifugation through 20% sucrose. Specific binding 
was estimated as total binding minus nonspecific binding (in the pres- 
ence of at least 20-fold excess of unlabeled antibodies). For evaluation 
of [125I]fibrinogen binding washed platelets (6.25 × 10S/ml) were pre- 
incubated for 20 min at 37°C in the absence or presence of monABs. 
After preincubation 20 I-tl of 0.15 ~tM [125I]fibrinogen was added to 80 
p.1 of platelets, incubated for 30 min at 37°C and bound and unbound 
radioactivities were separated by centrifugation through 20% sucrose. 
2.5. GPIIb-IIIa capture assay 
Washed platelets at a concentration of 5 × 10S/ml were incubated 
without any additions or in the presence of RGDS, RGES or CRC54 
for 20-30 rain at 37°C, medium was supplemented with 0.5 mM 
phenylmethylsulfonylfluoride and platelets were lysed with 1% Triton 
X-100 for 30 min on ice and undissolved material was spun down at 
10 000 × g for 5 min. Plates tbr capture assay (high-affinity binding 96- 
multiwells, Nunc, Denmark) were coated with monABs at a concen- 
tration of 10 ~tg/ml in phosphate buffered saline (PBS) for 1 h at 37°C, 
washed with PBS containing 0.05% Tween (PBS/Tween) and blocked 
with 1% BSA in PBS for 1 h at 37°C. 100 ~tl of platelet lysates was 
added to precoated wells and incubated for 1 h at 37°C. Wells were 
washed with PBS/Tween and affinity purified rabbit anti-GPIIb-IIIa 
polyclonal antibodies were added to the wells at a concentration of 
1 Ixg/ml and incubated for 30 min at 37°C. After washing goat anti- 
rabbit IgG antibodies conjugated with peroxidase (BioRad, Rich- 
mond, CA) were added at 1/2000 dilution and incubated for 30 min 
at 37°C. Plates were washed with PBS/Tween and PBS and color 
reaction was developed using 1,2-phenylenediamine. 
2.6. Platelet adhesion 
24-Well plates (Nunc, Denmark) were coated with fibrinogen or 
fibronectin at a concentration of 10 I.tg/ml in PBS for 1 h at 37°C, 
washed with PBS and blocked with 2% BSA in PBS for 1 h at 37°C. 
Control wells were treated with BSA only. 200 ~tl of 51Cr-labeled 
platelets at indicated concentrations was added into the wells and 
incubated without any additions or in the presence of monABs for 
1 h at 370C. Unattached platelets were washed off and bound radio- 
activity was collected with 1 M NaOH. 
2.7. Platelet aggregation 
Aggregation was studied in PRP (platelet count 2.5 × 10S/ml) or in 
washed platelet suspension (platelet count 3× 10S/ml) by measuring 
the mean size of platelet aggregates using a highly sensitive method 
based on the registration of optical density fluctuations in platelet 
suspension [20]. Measurements were performed in a BIOLA Aggrega- 
tion Analyzer (BIOLA Ltd., Russia) at 37°C and a stirring rate of 800 
rpm. 
3. Results and discussion 
Anti-GPI Ib- I I Ia monAB CRC54 has been partially de- 
scribed previously [8] and was shown to be conformation-de- 
pendent since it bound weakly to resting platelets but binding 
was increased after platelet adhesion or dissociation of GPIIb- 
I I Ia complex with EDTA. According to its ability to blot 
GPI Ib- I I Ia chymotryptic fragments the CRC54 epitope was 
mapped within the first 100 N-terminal residues of GPI I Ia [8]. 
In this study we used previously described conformation-de- 
pendent monABs to test if CRC54 epitope could overlap or 
be sterically close to other conformation-dependent pitopes 
of GPIIb-I I Ia. Anti-LIBS antibodies LIBSI,  LIBS2 and 
LIBS6 [5], PMI-1 [4,14], pl-80 [13] and antibody pl-55, which 
recognizes the activated conformation of GPI Ib- I I Ia [10], 
were tested in these experiments and none of them blocked 
binding of [xzsI]CRC54 to adherent platelets (Table 1). Some 
increase of binding in the presence of LIBS1 and LIBS2 might 
be explained by conformational changes in the complex 
mediated by the interaction with these antibodies. No compe- 
tition between CRC54 and other conformation-dependent 
antibodies demonstrated that their epitopes are located in 
different regions of GPIIb-I I Ia. It was shown earlier that 
CRC54 is able to blot GPI I Ia under both nonreduced and 
reduced conditions [8]. Unlike CRC54 other conformation- 
dependent antibodies which have been characterized by im- 
munoblotting under nonreduced conditions were unable to 
blot reduced GPI I Ia [5,6]. All these data taken together in- 
dicate the unique specificity of CRC54. 
In the previous paper [8] using low concentrations of 
[125I]CRC54 we were unable to detect significant differences 
in CRC54 binding to control platelets and platelets treated 
with thrombin or RGD peptide. In this study we repeated 
these experiments using high concentrations, up to 0.33 laM 
(50 ~tg/ml), of [125I]CRC54. Under these conditions CRC54 
binding to resting platelets did not exceed 5000 molecules 
per platelet which amounted to ,~ 10% of GPI Ib- I I Ia mole- 
cules present on the platelet surface. Binding in the presence 
of RGDS or thrombin was several times higher than to resting 
platelets although still lower than to platelets treated with 
EDTA (Fig. 1A). Thus it has been shown that changes in 
GPI Ib- I I Ia detected by CRC54 could be induced by the oc- 
cupation of GPI Ib- I I Ia with RGD peptide, thrombin-induced 
platelet activation or platelet adhesion as was demonstrated 
earlier [8]. These data indicate that CRC54 is directed against 
the LIBS epitope. In ease of thrombin-induced platelet activa- 
tion or platelet adhesion exposure of the CRC54 LIBS epitope 
is, presumably, mediated by the interaction of GPI Ib- I I Ia 
with the endogenous fibrinogen which is released from acti- 
vated platelets. 
We also compared binding to platelets of CRC54 IgG mo- 
lecule and CRC54 Fab fragments testing the hypothesis that 
low binding of CRC54 IgG to resting platelets might be due 
to the steric inaccessibility of the epitope for the IgG mole- 
cule. The level of [125I]CRC54 Fab binding to resting platelets 
was still low and almost the same as that of [12~I]CRC54 IgG 
(Fig. 1 B) although the binding of CRC54 Fab to EDTA-treat- 
Table 1 
Binding of [12~I]CRC54 with adherent platelets in the presence of 
different conformation-dependent anti-GPIIb-Ilta monABs 
Antibody % of [125I]CRC54 specific binding n 
LIBS1 218 + 21 3 
LIBS2 169 + 26 3 
LIBS6 79 + 8 3 
PMI-1 112 + 47 3 
pl-55 120 1 
pl-80 134 1 
[t2~I]CRC54 was added to adherent platelets at a concentration of 
6.67 nM (1 Ixg/ml), and unlabeled antibodies were added at -100- 
fold excess. Level of [125I]CRC54 specific binding (inhibited by the 
excess of unlabeled CRC54 and usually 90-95% of total binding) 
was taken as 100%. Means + SEM are given for n = 3. 
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ed platelets was increased to the same extent as the binding of 
CRC54 IgG, indicating that the Fab fragment has the same 
binding capacity as the whole IgG. So these data have shown 
that CRC54 epitope is inaccessible not only to the IgG mo- 
lecule but to its Fab fragment hat is ,~ 3 times smaller than 
intact antibody. 
The effects of CRC54 on platelet aggregation were studied 
by measuring the mean size of platelet aggregates u ing a new 
highly sensitive method based on the evaluation of optical 
density fluctuations in platelet suspension [20]. CRC54 in- 
duced platelet aggregation both in PRP (Fig. 2A) and in 
washed platelet suspension (Fig. 2B). High concentrations of
antibody were added to stimulate detectable aggregation and 
the intensity of the aggregation response was not saturated 
even at 1 ktM (150 ~tg/ml) of CRC54 (Fig. 2A). In washed 
platelet suspension the addition of exogenous fibrinogen was 
essential for CRC54-induced aggregation (Fig. 2B). Much 
lower concentrations and a routine turbidometric method 
were used in the initial study of CRC54 and that is why the 
aggregation response was not detected in a previous paper [8]. 
Fab fragments of CRC54 were also able to stimulate platelet 
aggregation (Fig. 2A,B), providing evidence that CRC54-in- 
duced aggregation is not mediated by platelet Fc receptor or 
possible bivalent binding of monAB. GPIIb-I I Ia blocking 
agents, like RGDS peptide and blocking antibody CRC64, 
completely inhibited CRC54-induced aggregation (Fig. 2C). 
However, inhibitors of intracellular metabolic pathways 
were less effective. Both prostaglandin E1 and the mixture 
of deoxyglucose and sodium azide, which are able to block 
platelet aggregation induced by physiological agonists, only 
partially inhibited the CRC54-induced aggregation response 
(Fig. 2D). These data indicate that interaction of CRC54 
with GPIIb-I I Ia is itself sufficient for the maintaining of plate- 
let aggregation, which is in accordance with the data obtained 
with antibodies against other regions of the complex and pur- 
ified or recombinant GPIIb-I I Ia expressed in model cells 
[6,11,12]. However, partial inhibition of CRC54-induced ag- 
gregation with prostaglandin E1 and deoxyglucose/sodium 
azide suggested stimulation of intracellular pathways that 
might be mediated by antibody-induced primary aggregation. 
Platelet aggregation induced by physiological agonists is 
mediated by the interaction of fibrinogen with GPIIb-I I Ia 
[1-3]. CRC54, like these agonists, was able to stimulate 
[125I]fibrinogen binding to platelets and this increase was in- 
hibited by the anti-GPIIb-IIIa blocking antibody, CRC64, 
showing binding specificity towards GPIIb-IIIa. At a concen- 
tration of labeled fibrinogen of 0.03 txM the binding level in 
the absence of any additions was 490 molecules per platelet, in 
Table 2 
Effects of CRC54 on the binding of anti-GPIIb-IIIa antibodies to 
platelets 
Addition 125I-antibody bound, molecules per platelet 
CRC64 pl-80 pl-55 
None 24 960 420 540 
CRC54 24 000 2840 15 120 
RGDS 29 960 3840 240 
Specific binding of 125I-labeled CRC64 (conformation-independent 
antibody), pl-80 (anti-LIBS antibody) or pl-55 (activation-dependent 
antibody) added to washed platelets at a concentration of 33 nM (5 
Ixg/ml) was evaluated without any additions, in the presence of 0.5 ~tM 
CRC54 or 1 mM RGDS. Means of two experiments are given. 
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Fig. 1. CRC54 binding to platelets. (A) Specific binding of 
[125I]CRC54 to washed platelets was measured without any addi- 
tions ((3) or in the presence of 1 mM RGDS (zx), 1 U/ml of throm- 
bin (v) or 5 mM EDTA (D). Mean of two experiments are given. 
In one experiment platelets were preincubated without any additions 
and in the presence of 1 mM RGES. Data were combined since no 
difference was detected. (B) Comparison of CRC54 IgG and CRC54 
Fab binding to platelets. Specific binding of [125I]CRC54 IgG (©,[2) 
or [125I]CRC54 Fab (e,ll) to washed platelets was measured without 
any additions (©,e) or in the presence of 5 mM EDTA ([2,11). 
the presence of 0.5 IxM CRC54 it was 1900 molecules per 
platelet and in the presence of 0.5 lxM CRC54 and 0.133 
txM CRC64 it was 600 molecules per platelet (n = 2). 
The effects of CRC54 on platelet interaction with GPIIb- 
II Ia ligands were also studied by measuring the adhesion of 
51Cr-labeled platelets to immobilized fibrinogen and fibronec- 
tin. In the presence of CRC54 the level of adhesion to both 
substrates was increased by 3~-fold (Fig. 3A,B). Most of the 
adherent platelets were spread out on the surface and no 
platelet aggregates were observed by phase-contrast micros- 
copy. The blocking antibody, CRC64, suppressed the adhe- 
sion of nonstimulated and CRC54-stimulated platelets to im- 
mobilized fibrinogen (Fig. 3A), showing that both basal and 
CRC54-induced adhesion to fibrinogen was mediated by 
GPIIb-IIIa. The adhesion of platelets to fibronectin was 
more complex. CRC64 had no effect on the adhesion of non- 
stimulated platelets to fibronectin but prevented the CRC54- 
induced increase of adhesion retaining it at the basal level 
(Fig. 3B). These results could be explained by the involvement 
of the specific fibronectin receptor, GPIc-IIa (aSl~l-integrin) 
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[21]. This receptor is present in a functional form on the sur- 
face of nonactivated platelets and might therefore mediate 
basal platelet adhesion to fibronectin which is not inhibited 
by GPIIb-IIIa blocking antibody. At the same time the in- 
crease of platelet adhesion to fibronectin in the presence of 
CRC54 is mediated by GPIIb-IIIa and thus is inhibited by 
CRC64. 
CRC54-induced conformational changes were registered 
using two other conformation-dependent monABs: anti- 
LIBS GPIIb antibody pl-80 [13] and activation-dependent 
antibody pl-55 [10]. Binding of both 125I-labeled antibodies 
to platelets was increased when platelets were incubated 
with CRC54, while binding of the conformation-independent 
antibody CRC64 was unaffected (Table 2). Binding of anti- 
LIBS antibody pl-80 was also increased when platelet GPIIb- 
l l Ia was occupied by RGDS, but the binding of activation- 
dependent antibody pl-55 was inhibited (Table 2), in accor- 
dance with the data obtained previously [13]. A 3B 
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Fig. 2. Platelet aggregation i duced by CRC54 IgG and CRC54 
Fab fragments. (A) Platelets in PRP were incubated with: 1 ~tM of 
control anti-GPIIb-IIIa ntibody VM16a (1), 0.5 ~tM CRC54 IgG 
(2), 1 ~tM CRC54 IgG (3), 0.8 I.tM CRC54 Fab (4) and 1.6 ~tM 
CRC54 Fab (5). (B) Washed platelets were incubated: without fibri- 
nogen and with 1 pM CRC54 lgG (1), with 1.65 p.M fibrinogen 
and 1 IxM CRC54 IgG (2), and with 1.65 ktM fibrinogen and 1.6 
ktM CRC54 Fab (3). (C) Platelets were preincubated in PRP for 
5 min: with no additions (1), with 0.133 p.M CRC64 (2); 1 mM 
RGDS (3) or 1 Ixg/ml prostaglandin E1 (4) and then CRC54 was 
added at the concentration of 0.5 I.tM. (D) Washed platelet were 
preincubated for 10 min with 10 mM dextrose (1) or 10 mM deoxy- 
glucose and 0.2% sodium azide (2) and then CRC54 was added at 
the concentration of 1.0 ~tM. Additions of CRC54 IgG or CRC54 
Fab are indicated by arrows. 
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Fig. 3. Effects of monABs CRC54 and CRC64 on the adhesion of 
51Cr-labeled platelets to fibrinogen (A) and fibronectin (B). Platelet 
adhesion was performed without antibodies (e), or in the presence 
of 0.4 gM CRC54 (I0, 0.133 gM CRC64 (&), or 0.4 gM CRC54 
and 0.133 gM CRC64 simultaneously (v). Level of adhesion in 
control wells coated with BSA only at platelet concentration of 
6 X 10S/ml in all samples was approximately the same and amounted 
to 1.2-1.6 x 106/well. Means of two experiments are given. 
The results obtained by measuring the binding of labeled 
antibodies in suspension were confirmed in the capture assay 
using platelet lysate as a source of GPIIb-IIIa and immobi- 
lized pl-80 and pl-55 as capture antibodies. Binding of GPIIb- 
IIIa from the lysate of CRC54-treated platelets to both anti- 
bodies was several times higher than binding from the lysate 
of control platelets (Fig. 4). In accordance with the data ob- 
tained in the binding assay with whole platelets, CRC54-in- 
duced binding to pl-80 was comparable to that induced by 
RGDS peptide and binding to pl-55 in the presence of 
RGDS was slightly lower than in control samples. Thus these 
results demonstrate hat CRC54 could induce conformational 
changes in GPIIb-IIIa registered by binding of other confor- 
mation-dependent a ibodies. 
The data presented in this work and in a previous paper 
describing antibody CRC54 [8], where the mapping of its 
epitope was performed, have demonstrated that the N-term- 
inal part of GPIIIa contains a LIBS epitope and thus is in- 
volved in conformational changes of the GPIIb-IIIa complex. 
It was shown that interaction of monAB with this epitope 
could stimulate binding of ligands to GPIIb-IIIa and subse- 
quent platelet aggregation. Using other conformation-depend- 
ent antibodies we detected conformational changes of GPIIb- 
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Fig. 4. Binding of GPIIb-IIIa from the platelet lysate to immobi- 
lized anti-GPIIb-IIIa conformation-dependent monABs. Washed 
platelets were preincubated without any additions (O), with 0.5 gM 
CRC54 (I) or 1 mM RGDS (*), lysed with Triton X-100 and 
binding of GPIIb-IIIa from the platelet lysate to anti-GPIIb LIBS 
antibody, pl-80 (A), or anti-GPIIb-IIIa activation-dependent anti- 
body, pl-55 (B), was evaluated by sandwich ELISA. 
II Ia which were induced by activating anti-LIBS antibody and 
reflected the increased binding ability of the complex. 
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